Immunomedics (IMMU) - moderated Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: ghettogoulash who wrote (63184)	7/24/2025 6:14:19 PM
From: ghettogoulash	3 Recommendations Recommended By erippetoe jhcimmu Olecranon Read Replies (2) of 63277

Roche also wonders wtf is up with the FDA. Meanwhile, Laura Loomer is on a crusade to remove Prasad, who "has wormed his way into a top FDA role as Director of the Center for Biologics Evaluation and Research (CBER) after he was appointed by RFK Jr." Roche stops shipping Sarepta gene therapy in some countries outside US share.google "Roche believes that the benefit-risk profile is positive in the ambulatory patient population,” the company explained in its statement. “As such, in countries that do not reference the FDA for approval and where Elevidys is approved, Roche will continue to supply and ship Elevidys to enable treatment of ambulatory patients, in consultation with local regulatory authorities... Roche is working to understand why the FDA has requested that shipments be paused in the ambulatory patient population, and is in contact with the appropriate health authorities globally to determine next potential steps."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next